For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Clinics in Columbus, Cleveland, Dayton, and Cincinnati have lost their licenses to distribute dangerous drugs after the Ohio ...

A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Popular weight loss injections including Ozempic, Wegovy and Mounjaro could increase the risk of thyroid cancer within the ...